alphaGalCer-RBD, a conjugate of the potent invariant natural killer T cell (iNKT) agonist alpha-Galactosylceramide (alphaGalCer) and the receptor-binding domain (RBD), serves as a self-adjuvanting lipoprotein that exhibits strong potential as a COVID-19 vaccine candidate. This compound effectively induces immunity against SARS-CoV-2 and its variants of concern by promoting the development of RBD-specific, cytokine-producing T cells.
Molecular Weight:
1119.6
Formula:
C60H118N4O14
Target:
SARS-CoV|||Others
* VAT and and shipping costs not included. Errors and price changes excepted
